Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 22, 2026Advances in TherapyOpen Access

BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians

View Full Paper
Ask AI
Bookmark
Share

Authors

RBRahul BanerjeeUniversity of WashingtonHHHamza HashmiMemorial Sloan Kettering Cancer CenterPCPreet M. ChaudharyUniversity of Southern California

Discussion

Loading...

Member takes

Overview

Modified Delphi study reveals expert consensus on personalized bridging therapy before CAR-T in relapsed multiple myeloma, highlighting tailored strategies to optimize safety and efficacy.

Key Points

  • To achieve clinical consensus on optimal bridging therapy selection and clinical objectives for patients with relapsed/refractory multiple myeloma preparing for CAR-T therapy.
  • Conducted a double-blind, three-round modified Delphi panel of 15 U.S. hematologist-oncologists actively treating relapsed/refractory multiple myeloma with CAR-T therapy.
  • Panelists achieved 100% consensus that the primary goals of bridging therapy are reducing disease burden and promoting CAR-T efficacy and safety.
  • Specific patient factors were linked to distinct clinical goals: aggressive disease required cytoreduction (100% consensus), high burden required preventing clinical decline (100%), and age ≥65 years or frailty favored disease stabilization (71%).
  • Talquetamab was preferred for bridging in later treatment lines by 66.7% of panelists, and 73.3% supported its use in earlier lines if approved.

Cite This Study

Banerjee et al. (2026) studied this question.

synapsesocial.com/papers/6a895ec3ca7ade938187ce31https://doi.org/10.1007/s12325-026-03737-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma2026 · 2 citations
  2. 2Current evidence and strategies for bridging therapy in CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphomas2026
  3. 3Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma2026
  4. 4Bridging Therapy's effects on clinical outcomes after commercial BCMA CAR T-cell therapy used in the standard of care treatment of relapsed and refractory multiple myeloma2025
  5. 5Understanding the Role and Clinical Management of Bridging Therapy During CAR T-Cell Therapy for Relapsed or Refractory Multiple Myeloma2025 · 4 citations